Read by QxMD icon Read

Hormones & Cancer

Rosalía I Cordo Russo, María F Chervo, Santiago Madera, Eduardo H Charreau, Patricia V Elizalde
Membrane overexpression of ErbB-2 (MErbB-2), a member of the ErbB family of receptor tyrosine kinases, occurs in 15-20% of breast cancers (BC) and constitutes a therapeutic target in this BC subtype (ErbB-2-positive). Although MErbB-2-targeted therapies have significantly improved patients' clinical outcome, resistance to available drugs is still a major issue in the clinic. Lack of accurate biomarkers for predicting responses to anti-ErbB-2 drugs at the time of diagnosis is also an important unresolved issue...
January 17, 2019: Hormones & Cancer
Tobias Else
No abstract text is available yet for this article.
December 7, 2018: Hormones & Cancer
Mauricio P Pinto, Matías Muñoz Medel, Diego Carrillo, Ignacio N Retamal, M Loreto Bravo, Yasna Valenzuela, Bruno Nervi, César Sánchez, Héctor Galindo, Carolina Ibañez, José Peña, Carlos Balmaceda, Jorge Madrid, Juan Briones, Javiera Torres, Flavia Nilo, Francisco J Guarda, Juan Carlos Quintana, Pilar Orellana, Sebastián Mondaca, Francisco Acevedo, Daniel Vicentini, Miguel Cordova-Delgado, Gareth I Owen, Marcelo Garrido
Neuroendocrine tumors (NETs) are relatively rare and highly heterogeneous neoplasms. Despite this, recent studies from North America and Central Europe have suggested an increase in incidence. In Latin America, NET data are scarce and scattered with only a few studies reporting registries. Our goal was to establish a NET registry in Chile. Here, we report the establishment and our first 166 NET patients. We observed a slight preponderance of males, a median age at diagnosis of 53 years and a median overall survival of 110 months...
November 22, 2018: Hormones & Cancer
Shafinaz Chowdhury, Lenore K Beitel, Rose Lumbroso, Enrico O Purisima, Miltiadis Paliouras, Mark Trifiro
The androgen-directed treatment of prostate cancer (PCa) is fraught with the recurrent profile of failed treatment due to drug resistance and must be addressed if we are to provide an effective therapeutic option. The most singular difficulty in the treatment of PCa is the failure to respond to classical androgen withdrawal or androgen blockade therapy, which often develops as the malignancy incurs genetic alterations and gain-of-function somatic mutations in the androgen receptor (AR). Physical cellular damaging therapeutic agents, such as radiation or activatable heat-generating transducers would circumvent classical "anti-functional" biological resistance, but to become ultimately effective would require directed application modalities...
February 2019: Hormones & Cancer
Courtney L Andersen, Michelle M Boisen, Matthew J Sikora, Tianzhou Ma, George Tseng, Swati Suryawanshi, Anda Vlad, Esther Elishaev, Robert P Edwards, Steffi Oesterreich
To investigate changes in estrogen receptor alpha (ERα) signaling during progression of endometriosis to endometriosis-associated ovarian cancer (EAOC) as a driver of malignant transformation. We procured tissue samples of normal endometrium, endometriosis (benign, atypical, concurrent with EAOC), and EAOC. We evaluated expression of a 236-gene signature of estrogen signaling. ANOVA and unsupervised clustering were used to identify gene expression profiles across disease states. These profiles were compared to profiles of estrogen regulation in cancer models from the Gene Expression Omnibus (GEO)...
December 2018: Hormones & Cancer
Waleeporn Kaewlert, Chadamas Sakonsinsiri, Nisana Namwat, Kanlayanee Sawanyawisuth, Piti Ungarreevittaya, Narong Khuntikeo, Napat Armartmuntree, Raynoo Thanan
CYP19A1, also called aromatase, is a key enzyme for converting androgens to estrogens of estrogen synthesis. Elevated serum estrogen and high expression levels of estrogen-related proteins are found in cholangiocarcinoma (CCA; bile duct cancer). However, the expression of CYP19A1 in relation to estrogen-related proteins, including estrogen receptors (ERα, ERβ, and GPR30) and an estrogen response protein (TFF1), has never been explored in CCA. In this study, we investigated the expressions of CYP19A1 and estrogen-related proteins in CCA tissues (n = 74; 51 males and 23 females) using immunohistochemistry...
December 2018: Hormones & Cancer
Yuzhe Yang, Jie Ying Chan, Nuri A Temiz, Douglas Yee
Insulin and insulin-like growth factor (IGF) signaling systems regulate breast cancer growth, progression, and metastasis. The insulin receptor substrates 1 and 2 (IRS1/2) transduce signaling from the type I IGF receptor (IGF-IR) and insulin receptor (InR) to mediate the biological effects of receptor activation. In breast cancer, IRS-1 plays a critical role in cancer cell proliferation while IRS-2 is associated with motility and metastasis. NT157, a small-molecule tyrphostin, downregulates IRS proteins in several model systems...
December 2018: Hormones & Cancer
Tung-Cheng Chang, Yu-Tang Chin, André Wendindondé Nana, Shwu-Huey Wang, Yu-Min Liao, Yi-Ru Chen, Ya-Jung Shih, Chun A Changou, Yu-Chen Sh Yang, Kuan Wang, Jacqueline Whang-Peng, Liang-Shun Wang, Steven C Stain, Ai Shih, Hung-Yun Lin, Chih-Hsiung Wu, Paul J Davis
Drug resistance complicates the clinical use of gefitinib. Tetraiodothyroacetic acid (tetrac) and nano-diamino-tetrac (NDAT) have been shown in vitro and in xenografts to have antiproliferative/angiogenic properties and to potentiate antiproliferative activity of other anticancer agents. In the current study, we investigated the effects of NDAT on the anticancer activities of gefitinib in human colorectal cancer cells. β-Galactoside α-2,6-sialyltransferase 1 (ST6Gal1) catalyzes EGFR sialylation that is associated with gefitinib resistance in colorectal cancers, and this was also investigated...
December 2018: Hormones & Cancer
Seong-Jang Kim, Sang-Woo Lee, Shin Young Jeong, Kyoungjune Pak, Keunyoung Kim
The purpose of the current study was to investigate the diagnostic performance of F-18 Fluorocholine (FCH) positron emission tomography/computed tomography (PET/CT) for localization of hyperfunctioning parathyroid gland in patients with hyperparathyroidism (HPT) through a systematic review and meta-analysis. The MEDLINE/PubMed and EMBASE database, from the earliest available date of indexing through April 30, 2018, were searched for studies evaluating the diagnostic performance of F-18 FCH PET/CT for localization of hyperfunctioning parathyroid gland in patients with HPT...
December 2018: Hormones & Cancer
Yi X Chan, Matthew W Knuiman, Mark L Divitini, David J Handelsman, John P Beilby, Bu B Yeap
Androgens, notably testosterone (T), have been implicated in development of several common cancers and prostate cancer; however, precise mechanisms remain unclear. This study assessed prospective associations of serum T, dihydrotestosterone (DHT) and estradiol (E2) with overall cancer (excluding skin cancer), prostate, colorectal and lung cancer risk in 1574 community-dwelling men aged 25-84 years. Sex hormones were assayed using mass spectrometry and men were followed for 20 years with outcomes ascertained using data linkage...
December 2018: Hormones & Cancer
Konstantinos Segkos, Kyle Porter, Leigha Senter, Matthew D Ringel, Fadi A Nabhan
There are limited data on the role of neck ultrasound (US) in the surveillance of patients with follicular thyroid cancer (FTC). Here, we analyze the likelihood of US to find structural disease in patients with FTC and evaluate if initial American Thyroid Association (ATA) risk stratification and the response to therapy categories [the latter based on thyroglobulin (Tg) levels] modify that likelihood. We conducted a retrospective cohort study of 32 patients with FTC in our institution. We included all patients with well-differentiated FTC who underwent total thyroidectomy and radioactive iodine (RAI) treatment without neck structural disease at the time of RAI and with Tg and US at least 6 months after RAI...
December 2018: Hormones & Cancer
Kayoung Lee, Jung Eun Yoo, Tuong Linh Nguyen, John Llewelyn Hopper, Yun-Mi Song
Mammographic density (MD) is a strong independent risk factor for breast cancer. It has been suggested that breast cancer is related to the exposure to circulating sex hormones. However, relations between MD and hormones have been inconsistent. In addition, such relations are mainly evaluated in Western populations. Therefore, we conducted a cross-sectional study in 396 cancer-free postmenopausal Korean women who had never used hormone replacement therapy. We assayed estradiol, testosterone, and sex hormone-binding globulin (SHBG) levels...
December 2018: Hormones & Cancer
Ashraf Khalil, Mark J Jameson
A lentivirus-mediated doxycycline-inducible pTRIPZ shRNAmir plasmid targeting IGF1R transcript was transfected into two head and neck squamous cell carcinoma (HNSCC) cell lines to silence IGF1R expression and to assess the effect of its downregulation on cisplatin sensitivity in vitro. In Cal27-regIGF1R and SCC25-regIGF1R cell lines, IGF1R protein expression was reduced by more than 90% after 72 h of incubation with doxycycline. Both basal and IGF-stimulated pIGF1R, pAKT, and pERK were significantly reduced, without influence on total AKT and ERK expression...
October 23, 2018: Hormones & Cancer
Yann Neuzillet, Jean-Pierre Raynaud, Jean-François Dreyfus, Camélia Radulescu, Mathieu Rouanne, Marc Schneider, Sylvie Krish, Morgan Rouprêt, Sarah J Drouin, Eva Comperat, Marc Galiano, Xavier Cathelineau, Pierre Validire, Vincent Molinié, Jean Fiet, Franck Giton, Thierry Lebret, Henry Botto
Failure rates after first-line treatment of localized prostate cancer (PCa) treatment remain high. Improvements to patient selection and identification of at-risk patients are central to reducing mortality. We aimed to determine if cancer aggressiveness correlates with androgen levels in patients undergoing radical prostatectomy for localized PCa. We performed a prospective, multicenter cohort study between June 2013 and June 2016, involving men with localized PCa scheduled to undergo radical prostatectomy...
October 6, 2018: Hormones & Cancer
André Wendindondé Nana, Szu Yuan Wu, Yu-Chen Sh Yang, Yu-Tang Chin, Tsai-Mu Cheng, Yih Ho, Wen-Shan Li, Yu-Min Liao, Yi-Ru Chen, Ya-Jung Shih, Yun-Ru Liu, Jens Pedersen, Sandra Incerpi, Aleck Hercbergs, Leroy F Liu, Jacqueline Whang-Peng, Paul J Davis, Hung-Yun Lin
Cancer resistance to chemotherapeutic agents is a major issue in the management of cancer patients. Overexpression of the ribonucleotide reductase regulatory subunit M2 (RRM2) has been associated with aggressive cancer behavior and chemoresistance. Nano-diamino-tetrac (NDAT) is a nanoparticulate derivative of tetraiodothyroacetic acid (tetrac), which exerts anticancer properties via several mechanisms and downregulates RRM2 gene expression in cancer cells. Resveratrol is a stilbenoid phytoalexin which binds to a specific site on the cell surface integrin αvβ3 to trigger cancer cell death via nuclear translocation of COX-2...
October 2018: Hormones & Cancer
Dan Zhang, Jianing Tang, Deguang Kong, Qiuxia Cui, Kun Wang, Yan Gong, Gaosong Wu
The incidence of thyroid cancer in females is significantly higher than that in males; however, females are more likely to have more favorable outcomes. We aimed to determine the characteristics of differentiated thyroid carcinoma (DTC) subtypes in males and females, and to compare their clinical behavior and survival. A total of 68,337 cases were recruited from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program. The disease-specific survival (DSS) of follicular variant papillary thyroid carcinoma (FVPTC) and follicular thyroid carcinoma (FTC) were similar to that of classical variant papillary thyroid carcinoma (CPTC) in male patients (FVPTC vs...
October 2018: Hormones & Cancer
Gowri Palanissami, Solomon F D Paul
Risk of cancer especially of colon, breast, and pancreas is high in diabetic and obese patients, with potential involvement of augmented expression of RAGE (receptor for advanced glycation end products) and its ligands, namely AGEs (advanced glycation end products), HMGB1 (high-mobility group box 1 protein), and S100 group of proteins. Studies have reported the involvement of RAGE activation by its ligands in growth and survival of cancers, including metastasis and poor prognosis. We propose that this receptor-ligand axis provides the molecular link between certain pre-existing states as hypoxia, hyperglycemia, glycation, inflammation, oxidative stress, and onset of cancers...
October 2018: Hormones & Cancer
Ana Sahores, Virginia Figueroa, María May, Marcos Liguori, Adrián Rubstein, Cynthia Fuentes, Britta M Jacobsen, Andrés Elía, Paola Rojas, Gonzalo R Sequeira, Michelle M Álvarez, Pedro González, Hugo Gass, Stephen Hewitt, Alfredo Molinolo, Claudia Lanari, Caroline A Lamb
Endocrine resistance may develop as a consequence of enhanced growth factor signaling. Fibroblast growth factor 2 (FGF2) consists of a low and several high molecular weight forms (HMW-FGF2). We previously demonstrated that antiprogestin-resistant mammary carcinomas display lower levels of progesterone receptor A isoforms (PRA) than B isoforms (PRB). Our aim was to evaluate the role of FGF2 isoforms in breast cancer progression. We evaluated FGF2 expression, cell proliferation, and pathway activation in models with different PRA/PRB ratios...
October 2018: Hormones & Cancer
Raffaele Hellweg, Ashley Mooneyham, Zenas Chang, Mihir Shetty, Edith Emmings, Yoshie Iizuka, Christopher Clark, Timothy Starr, Juan H Abrahante, Florian Schütz, Gottfried Konecny, Peter Argenta, Martina Bazzaro
Despite advances in surgical technique and adjuvant treatment, endometrial cancer has recently seen an increase in incidence and mortality in the USA. The majority of endometrial cancers can be cured by surgery alone or in combination with adjuvant chemo- or radiotherapy; however, a subset of patients experience recurrence for reasons that remain unclear. Recurrence is associated with chemoresistance to carboplatin and paclitaxel and consequentially, high mortality. Understanding the pathways involved in endometrial cancer chemoresistance is paramount for the identification of biomarkers and novel molecular targets for this disease...
October 2018: Hormones & Cancer
Sandra Pekic, Ivan Soldatovic, Dragana Miljic, Marko Stojanovic, Mirjana Doknic, Milan Petakov, Vera Popovic
People are at higher risk for malignancy as they get older or have a strong family history of cancer. This study aims to collect family history of cancer in a large cohort of patients with pituitary adenomas (PA) in outpatient clinic from years 2005-2017. Overall, 46.6% of 1062 patients with PA had a family member affected with cancer. Breast cancer in family members was reported in 15.3% of patients with prolactinomas which was significantly higher than in families of patients with non-functioning pituitary adenomas (NFPA) (10...
September 8, 2018: Hormones & Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"